Clinical trial
Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer
NCT00003126 · Loyola University, Other · Completed
Key facts
| NCT number | NCT00003126 |
|---|---|
| Title | Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer |
| Official title | A Randomized Controlled Phase III Adjuvant Trial of High-Dose Bolus IL-2 in Patients With High-Risk Renal Cell Carcinoma |
| Lead sponsor | Loyola University, Other |
| Collaborators | Chiron Corporation Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Kidney Cancer |
| Intervention type | Drug |
| Interventions | Interleukin-2 |
| Enrollment | 69 |
| Start date | Jun 1, 1997 |
| Primary completion | Aug 1, 2002 |
| Completion | Aug 1, 2002 |
| First posted | Oct 28, 2003 |
| Last update posted | Jan 4, 2017 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: